The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.
Revolution Medicines, a US-based precision oncology drug developer exploiting research from multiple universities, set terms yesterday for an initial public offering set to raise up to $160m.
The company set the range for the offering at $14 to $16 and plans to issue 10 million shares on the Nasdaq Global Market next week.
Founded in 2014, Revolution is working on therapies for a range of cancer indications. It is focusing on inhibitors of frontier targets, proteins that…
